Aflibercept

Drug Profile

Aflibercept

Alternative Names: AVE-0005; BAY-865321; Eylea; Eylia; VEGF Trap (R1R2); VEGF Trap-Eye; Zaltrap; Ziv-aflibercept

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Yakuhin; Centre Oscar Lambret; GERCOR; Guys Hospital; Moorfields Eye Hospital; National Cancer Institute (USA); Regeneron Pharmaceuticals; Sanofi; sanofi-aventis; University of Ulm
  • Class Antineoplastics; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Branch retinal vein occlusion; Central retinal vein occlusion; Choroidal neovascularisation; Colorectal cancer; Diabetic macular oedema; Wet age-related macular degeneration
  • Registered Diabetic retinopathy
  • Phase III Glaucoma
  • Phase II Central serous chorioretinopathy
  • Phase I Non-Hodgkin's lymphoma; Solid tumours
  • No development reported Malignant ascites; Ovarian cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 01 Jan 2017 Sanofi and Regeneron Pharmaceuticals complete a phase III trial in Colorectal cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA, Canada, Chile, Brazil, Mexico, Puerto Rico, the UK, Belgium, Czech Republic, Denmark, Finland, Germany, Ireland, Italy, Netherlands, Sweden, Slovenia, Spain, Norway, Turkey, Israel, Lebanon, Russia and Thailand (NCT01571284)
  • 02 Dec 2016 Bayer Yakuhin terminates enrolment phase III trial in Choroidal neovascularisation in Japan (UMIN000012493)
  • 01 Nov 2016 Bayer initiates the phase IIIb VIOLET trial for Diabetic macular oedema in Portugal and Poland (Intravitreal) (NCT02818998) after November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top